Disclosures: Patrick INGILIZ: GILEAD: Speaking and Teaching, Abbvie: Speaking and Teaching, ViiV: Speaking and Teaching, Erwan Vo Quang: Nothing to Disclose, Maud Lemoine: Nothing to Disclose, Amie Ceesay: Nothing to Disclose, Gibril Ndow: Nothing to Disclose, Marie-Noelle Hilleret: Nothing to Disclose, Laure Bordy: Nothing to Disclose, Thomas Decaens: Nothing to Disclose, Anne-Laure Mazialivoua: Nothing to Disclose, Yusuke Shimakava: Nothing to Disclose, Alhagie Bakoteh: Nothing to Disclose, Jean-Michel Pawlotsky: Abbvie: Speaker, Abbott: Advisor, Gilead: Speaking and Teaching, GSK: Advisor, Isabelle CHEMIN: Nothing to Disclose, Stphane Chevaliez: Nothing to Disclose, Vincent Leroy: Nothing to Disclose 448 HEPATIC STEATOSIS IS ASSOCIATED WITH HBSAG CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION Emin Bodakci 1 Saba Kiremiti 1 Serkan Duman 1 Zeynep Melekoglu Ellik 1 Mesut Gumussoy 1 Sevinc Tue Guvenir 1 Volkan YILMAZ 1 ramazan erdem er 1 Fatih Karakaya 1 Hale Gokcan 1 Atilla Elhan 1 Berna Savas 1 Ramazan Idilman 1 , 1 Ankara University Background: The present study aimed to determine the effect of hepatic steatosis detected by liver biopsy on HBsAg seroclearance and disease outcome in hepatitis B virus (HBV)-infected patients

Single Administration of P2ta (AB103), a CD28 Antagonist Peptide, Prevents Inflammatory and Thrombotic Reactions and Protects Against Gastrointestinal Injury in Total-Body Irradiated Mice
Step 5: Aftercare: Once the treatment is complete, you may feel an immediate boost in energy
Heres what you can expect from this service: Tailored Treatment Plan : Based on your individual goals